Skip to main content
. 2018 Sep 18;38(12):2233–2242. doi: 10.1007/s00296-018-4159-1

Fig. 1.

Fig. 1

Summary of the study design. a Patients whose ESR and CRP improved by ≥ 50% at week 14. b Patients whose ESR and CRP did not improve by ≥ 50% or increased. c Primary end point. ESR erythrocyte sedimentation rate, CRP C-reactive protein, PTX3 pentraxin-3, sHLA-E soluble human leukocyte antigen-E, TNFα tumor necrosis factor-α, IL-6 interleukin-6, ITAS-2010 Indian Takayasu Clinical Activity Score, PET–CT positron emission tomography–computed tomography